HIV protease inhibitors: Garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 8-9, 2010, Pages 495-505

  Berginc, Katja ^a   Trdan, Tina ^a   Trontelj, Jurij ^a   Kristl, Albin ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

aged garlic extract; CYP3A4; darunavir; intestine; saquinavir

Indexed keywords

CYTOCHROME P450 3A4; DARUNAVIR; DRUG METABOLITE; GARLIC EXTRACT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2; RITONAVIR; SAQUINAVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; DRUG ABSORPTION; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; DRUG TRANSPORT; FIRST PASS EFFECT; GARLIC; HUMAN; IN VITRO STUDY; INTESTINE CELL; LIVER MICROSOME; MALE; NONHUMAN; RAT;

ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CYTOCHROME P-450 CYP3A; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; ENTEROCYTES; GARLIC; HIV PROTEASE INHIBITORS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; JEJUNUM; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PLANT EXTRACTS; RATS; RATS, WISTAR; RITONAVIR; SAQUINAVIR; SULFONAMIDES;

EID: 78649660582     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.730     Document Type: Article

References (18)

1. Aungst BJ,. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv Drug Deliv Rev 1999; 39: 105-116. DOI: 10.1016/S0169-409X(99)00022-8. (Pubitemid 29430232)
2. Fitzsimmons ME, Collins JM,. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Drug Metab Dispos 1997; 25: 256-266. DOI: 0090-9556/97/2502-0256-266$02.00/0.
3. Vermeir M, Durand-Lachau S, Mannens G, Cuyckens F, van Hoof B, Raoof A,. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos 2009; 37: 809-820. DOI: 10.1124/dmd.108.024109.
4. Palombo MS, Singh Y, Sinko PJ,. Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy. J Drug Del Sci Tech 2009; 19: 3-14.
5. Wynn GH, Zapor MJ, Smith BH, et al,. Antiretrovirals, Part 1: Overview, history, and focus on protease inhibitors. Psychosomatics 2004; 45: 262-269.
6. Foster BC, Arnason JT, Briggs CJ,. Natural health products and drug disposition. Annu Rev Pharmacol Toxicol 2005; 45: 203-226. DOI: 10.1146/annurev.pharmtox.45.120403.095950. (Pubitemid 40261803)
7. Lee LS, Andrade ASA, Flexner C,. Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Curr Infect Dis Rep 2006; 43: 1052-1059. DOI: 10.1086/507894. (Pubitemid 44631108)
8. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J,. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34: 234-238. DOI: 10.1086/324351. (Pubitemid 34028358)
9. Fugh-Berman A, Ernst E,. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001; 52: 587-595. DOI: 10.1046/j.0306-5251.2001.01469.x.
10. Berginc K, Žakelj S, Kristl A,. In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. Eur J Nutr 2010; 49: 373-384. DOI: 10.1007/s00394-010-0095-x.
11. Berginc K, Milisav I, Kristl A,. Garlic flavonoids and organosulfur compounds: the impact on saqunavir's and darunavir's hepatic pharmacokinetics. Accepted for publication in Drug Metab Pharmacokin.
12. Foster BC, Foster MS, Vandenhoek S, et al,. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharmaceut Sci 2001; 4: 176-184. DOI: 11466175.
13. van den Bout-van den Beukel CJP, Koopmans PP, van der Ven AJAM, De Smet PAGM, Burger DM,. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev 2006; 38: 477-514. DOI: 10.1080/03602530600754065. (Pubitemid 44167199)
14. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW,. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 5: 35-98. DOI: 10.1081/DMR-120018248. (Pubitemid 36249785)
15. Zvonar A, Berginc K, Kristl A, Gašperlin M,. Microencapsulation of self-microemulsifying system: improving solubility and permeability of furosemide. Int J Pharm 2010; 388: 151-158. DOI: 10.1016/j.ijpharm.2009.12.055.
16. Gupta A, Zhang Y, Unadkat J-D, Mao Q,. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 2004; 310: 334-341. DOI: 10.1124/jpet.104. 065342. (Pubitemid 38812728)
17. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callagan R,. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000; 58: 624-632. DOI: 10953057.
18. Kageyama M, Namiki H, Fukushima H, et al,. Effect of chronic administration of ritonavir on function of cytochrome P4503A and P-glycoprotein in rats. Biol Pharm Bull 2005; 28: 130-137. DOI: 15635177.